{
    "ticker": "EYEG",
    "name": "EyeGate Pharmaceuticals, Inc.",
    "description": "EyeGate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of eye diseases and disorders. Founded in 2010 and based in Waltham, Massachusetts, EyeGate is dedicated to addressing unmet medical needs in ophthalmology through its proprietary drug delivery platform and drug candidates. The company's lead product candidate, EGP-437, is a novel treatment designed for ocular inflammation and pain, utilizing the EyeGate II Delivery System, which enables the non-invasive delivery of medication directly to the eye. EyeGate aims to enhance therapeutic efficacy and improve patient outcomes by minimizing systemic exposure and maximizing localized drug absorption. With a robust pipeline of formulations and collaborations with leading research institutions, EyeGate is poised to make significant contributions to the field of ophthalmic medicine. The company is committed to advancing its clinical programs and bringing effective therapies to market, in order to improve the quality of life for patients suffering from various eye conditions.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Waltham, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.eyegatepharma.com",
    "ceo": "David E. L. J. H. M. W. E. R. D. M. K. H. M. V. G. B. E.",
    "social_media": {
        "twitter": "https://twitter.com/EyeGatePharma",
        "linkedin": "https://www.linkedin.com/company/eyegate-pharmaceuticals-inc/"
    },
    "investor_relations": "https://investors.eyegatepharma.com",
    "key_executives": [
        {
            "name": "David E. L. J. H. M. W. E. R. D. M. K. H. M. V. G. B. E.",
            "position": "CEO"
        },
        {
            "name": "Michael A. H. McCormick",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ophthalmic Therapeutics",
            "products": [
                "EGP-437"
            ]
        }
    ],
    "seo": {
        "meta_title": "EyeGate Pharmaceuticals, Inc. | Innovative Ocular Therapies",
        "meta_description": "Explore EyeGate Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for eye diseases. Learn about their lead product, EGP-437, and their commitment to improving patient outcomes.",
        "keywords": [
            "EyeGate Pharmaceuticals",
            "Ophthalmic Therapeutics",
            "EGP-437",
            "Eye Diseases",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does EyeGate Pharmaceuticals specialize in?",
            "answer": "EyeGate Pharmaceuticals specializes in developing innovative therapeutics for the treatment of eye diseases and disorders."
        },
        {
            "question": "What is EyeGate's lead product candidate?",
            "answer": "EyeGate's lead product candidate is EGP-437, designed for ocular inflammation and pain."
        },
        {
            "question": "Where is EyeGate headquartered?",
            "answer": "EyeGate is headquartered in Waltham, Massachusetts, USA."
        },
        {
            "question": "When was EyeGate founded?",
            "answer": "EyeGate was founded in 2010."
        }
    ],
    "competitors": [
        "RGC",
        "KOD",
        "RCUS",
        "OCGN"
    ],
    "related_stocks": [
        "AAPL",
        "AMZN",
        "MSFT",
        "GOOGL"
    ]
}